ERBB2 and breast cancer: The key finding in this study is the proposal of a new echocardiographic parameter, \documentclass[12pt]{minimal}\usepackage{amsmath}\usepackage{wasysym}\usepackage{amsfonts}\usepackage{amssymb}\usepackage{amsbsy}\usepackage{mathrsfs}\usepackage{upgreek}\setlength{\oddsidemargin}{-69pt}\begin{document}$$\:{v}_{{E}^{{\prime\:}}}$$\end{document}, which could serve as a predictor of a higher risk of moderate-to-severe CTRCD in patients with breast cancer who are scheduled to receive anti-HER2 therapies or anthracyclines.